REFERENCES

1. Ng QX, Ong C, Chan KE, et al. Comparative policy analysis of national rare disease funding policies in Australia, Singapore, South Korea, the United Kingdom and the United States: a scoping review. Health Econ Rev 2024;14:42.

2. Austin CP, Cutillo CM, Lau LPL, et al. Future of rare diseases research 2017-2027: an IRDiRC perspective. Clin Transl Sci 2018;11:21-7.

3. Monaco L, Zanello G, Baynam G, et al. Research on rare diseases: ten years of progress and challenges at IRDiRC. Nat Rev Drug Discov 2022;21:319-20.

4. Beaverson KL, Julkowska D, Letinturier MCV, et al. The IRDiRC chrysalis task force: making rare disease research attractive to companies. Ther Adv Rare Dis 2023;4:26330040231188979.

5. Levine JA, Stemitsiotis C. De-risking rare disease acquisitions: a win-win-win for patients, biotech and investors. Nat Rev Drug Discov 2024;23:10-1.

6. Jekunen A. Decision-making in product portfolios of pharmaceutical research and development-managing streams of innovation in highly regulated markets. Drug Des Devel Ther 2014;2014:2009-16.

7. Koleva-Kolarova R, Buchanan J, Vellekoop H, et al. Financing and reimbursement models for personalised medicine: a systematic review to identify current models and future options. Appl Health Econ Health Policy 2022;20:501-24.

8. Postma MJ, Noone D, Rozenbaum MH, et al. Assessing the value of orphan drugs using conventional cost-effectiveness analysis: is it fit for purpose? Orphanet J Rare Dis 2022;17:157.

9. Khachatryan A, Read SH, Madison T. External control arms for rare diseases: building a body of supporting evidence. J Pharmacokinet Pharmacodyn 2023;50:501-6.

10. Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis 2011;6:42.

11. National Center for Advancing Translational Sciences. Our impact on rare diseases. Available from: https://ncats.nih.gov/research/our-impact/our-impact-rare-diseases [Last accessed on 2 Sep 2024].

12. European Union. Collaboration: a key to unlock the challenges of rare diseases research. Available from: https://data.europa.eu/doi/10.2777/371608 [Last accessed on 2 Sep 2024].

13. Japan Agency for Medical Research and Development. Available from: https://www.amed.go.jp/en/program/list/11/02/003.html [Last accessed on 2 Sep 2024].

14. Au service de la science. Agence nationale de la recherche. Accessed May 16, 2024. Available from: https://anr.fr/ [Last accessed on 2 Sep 2024].

15. Amselem S, Gueguen S, Weinbach J, Clement A, Landais P. RaDiCo Program. RaDiCo, the French national research program on rare disease cohorts. Orphanet J Rare Dis 2021;16:454.

16. Rare diseases and European reference networks. Available from: https://health.ec.europa.eu/european-reference-networks_en [Last accessed on 2 Sep 2024].

17. SBIR And STTR funding opportunities. Non-dilutive funding for early-stage research and development. Available from: https://seed.nih.gov/small-business-funding/find-funding/sbir-sttr-funding-opportunities [Last accessed on 2 Sep 2024].

18. Patterson AM, O'Boyle M, VanNoy GE, Dies KA. Emerging roles and opportunities for rare disease patient advocacy groups. Ther Adv Rare Dis 2023;4:26330040231164425.

19. EIC Accelerator. Available from: https://eic.ec.europa.eu/eic-funding-opportunities/eic-accelerator_en [Last accessed on 2 Sep 2024].

20. Rennane S, Baker L, Mulcahy A. Estimating the cost of industry investment in drug research and development: a review of methods and results. Inquiry 2021;58:469580211059731.

21. López JC, Suojanen C. Harnessing venture philanthropy to accelerate medical progress. Nat Rev Drug Discov 2019;18:809-10.

22. NEXT 2022 - redefining the possible. Available from: https://globalgenes.org/report/next-2022-redefining-the-possible/ [Last accessed on 2 Sep 2024].

23. Making genetic therapies affordable and accessible. Available from: https://innovativegenomics.org/atf-report/ [Last accessed on 2 Sep 2024].

24. General Annexes. Horizon 2020 - work programme 2018-2020. Available from: https://ec.europa.eu/research/participants/data/ref/h2020/other/wp/2018-2020/annexes/h2020-wp1820-annex-g-trl_en.pdf [Last accessed on 2 Sep 2024].